Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Announces Progress in Hepatitis C and E Programs
Atea Pharmaceuticals Inc. reported its financial results for the third quarter ended September 30, 2025. The company reported cash, cash equivalents, and marketable securities totaling $329.3 million as of the end of the quarter, compared to $454.7 million at the end of the previous period. Working capital was $316.0 million, down from $443.8 million. Total assets were $343.0 million, with total liabilities of $27.2 million and total stockholder's equity of $315.8 million. Atea provided a business update, noting that patient enrollment is on track in its global Phase 3 program for the treatment of hepatitis C virus (HCV), with topline results from the North America trial expected in mid-2026. The company also announced new data showing that bemnifosbuvir has a unique dual mechanism against HCV, and presented results supporting the combination of bemnifosbuvir/ruzasvir as a potential best-in-class therapy for HCV. Additionally, Atea announced the initiation of a new hepatitis E virus (HEV) development program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-277627), on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.